Katia Mancuso

17PUBLICATIONS
67CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyVirologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 21, 2026
Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights.

|Mar 11, 2026
Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

K Mancuso, S Masci, M Talarico

|Dec 09, 2025
Belamaf: is renal toxicity an overlooked side effect?

Gisella Vischini, Paola Tacchetti, Laura Pavan

|Aug 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

|May 14, 2025
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.

Katia Mancuso, Marco Talarico, Enrica Manzato

|Apr 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

Pageof 3

Frequent Collaborators

10 joint publications

Elena Zamagni

6 joint publications

Michele Cavo

6 joint publications

Simona Barbato

5 joint publications

Ilaria Rizzello